CYP2D6 polymorphism is not associated with essential tremor

被引:17
作者
Agundez, JAG
JimenezJimenez, FJ
Tejeda, R
Ledesma, MC
OrtiPareja, M
Gasalla, T
Molina, JA
Ruiz, J
Coria, F
Duarte, J
Vazquez, A
Ladero, JM
Benitez, J
机构
[1] UNIV EXTREMADURA, SCH MED, DEPT PHARMACOL & PSYCHIAT, BADAJOZ, SPAIN
[2] HOSP UNIV PRINCIPE ASTURIAS, NEUROL SERV, ALCALA DE HENARES, SPAIN
[3] SAN CARLOS UNIV HOSP, GASTROENTEROL SERV, MADRID, SPAIN
[4] HOSP UNIV DOCE OCTUBRE, NEUROL SERV, MADRID, SPAIN
[5] HOSP GEN SEGOVIA, NEUROL SERV, MADRID, SPAIN
[6] HOSP UNIV SAN CARLOS, NEUROL SERV, MADRID, SPAIN
关键词
essential tremor; debrisoquine; polymorphism; etiology; genetics;
D O I
10.1159/000113168
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Recent reports have shown an association between cytochrome P450IID6 (CYP2D6) polymorphism and Parkinson's disease. We investigated the association between this polymorphism and the risk for developing essential tremor (ET). Leukocytic DNA from 91 unrelated ET patients and a control group of 258 unrelated healthy individuals was studied for the occurrence of eight different CYP2D6 allelic variants by using allele-specific PCR amplification XbaI and EcoRI-RFLP's analyses. The prevalence for these allelic variants in the ET and control groups were, respectively: CYP2D6*1 76.9 and 78.7%, CYP2D6*2 0.5 and 0.2%, CYP2D6*3 0 and 1%, CYP2D6*4 12.1 and 12.2%, CYP2D6*5 1.6 and 1.7%, CYP2D6*9 4.4 and 2.9%, CYP2D6*2x2 4.4 and 3.2%. The prevalence of subjects with absent CYP2D6 activity (those carrying two defect genes) was 1.1 and 3.1% in ET and control groups, respectively. Both groups studied were in Hardy-Weinberg equilibrium. These results indicate that mutations at the CYP2D6 gene do not seem to be a major factor in determining susceptibility to ET, and reinforces the view that ET and parkinsonism are distinct conditions.
引用
收藏
页码:99 / 104
页数:6
相关论文
共 57 条
[1]   GENETIC-BASIS FOR DIFFERENCES IN DEBRISOQUIN POLYMORPHISM BETWEEN A SPANISH AND OTHER WHITE-POPULATIONS [J].
AGUNDEZ, JAG ;
MARTINEZ, C ;
LEDESMA, MC ;
LADONA, MG ;
LADERO, JM ;
BENITEZ, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (04) :412-417
[2]  
Agundez JAG, 1995, ACTA NEUROL SCAND, V92, P464
[3]   PREVALENCE OF CYP2D6 GENE DUPLICATION AND ITS REPERCUSSION ON THE OXIDATIVE PHENOTYPE IN A WHITE-POPULATION [J].
AGUNDEZ, JAG ;
LEDESMA, MC ;
LADERO, JM ;
BENITEZ, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (03) :265-269
[4]   ASSOCIATION BETWEEN THE OXIDATIVE POLYMORPHISM AND EARLY-ONSET OF PARKINSONS-DISEASE [J].
AGUNDEZ, JAG ;
JIMENEZJIMENEZ, FJ ;
LUENGO, A ;
BERNAL, ML ;
MOLINA, JA ;
AYUSO, L ;
VAZQUEZ, A ;
PARRA, J ;
DUARTE, J ;
CORIA, F ;
LADERO, JM ;
ALVAREZ, JC ;
BENITEZ, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (03) :291-298
[5]   MUTANT DEBRISOQUINE HYDROXYLATION GENES IN PARKINSONS-DISEASE [J].
ARMSTRONG, M ;
DALY, AK ;
CHOLERTON, S ;
BATEMAN, DN ;
IDLE, JR .
LANCET, 1992, 339 (8800) :1017-1018
[6]   ARG296 TO CYS296 POLYMORPHISM IN EXON-6 OF CYTOCHROME-P-450-2D6 (CYP2D6) IS NOT ASSOCIATED WITH MULTIPLE SYSTEM ATROPHY [J].
BANDMANN, O ;
WENNING, GK ;
QUINN, NP ;
HARDING, AE .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1995, 59 (05) :557-557
[7]   NEW DATA ON THE GENETICS OF PARKINSONS-DISEASE [J].
BARBEAU, A ;
POURCHER, E .
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1982, 9 (01) :53-60
[8]   OXIDATIVE POLYMORPHISM OF DEBRISOQUINE IS NOT RELATED TO THE RISK OF ALZHEIMERS-DISEASE [J].
BENITEZ, J ;
BARQUERO, MS ;
CORIA, F ;
MOLINA, JA ;
JIMENEZJIMENEZ, FJ ;
LADERO, JM .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1993, 117 (1-2) :8-11
[9]   ISOLATED TREMOR AND DISRUPTION OF THE NIGROSTRIATAL DOPAMINERGIC SYSTEM - AN F-18 DOPA PET STUDY [J].
BROOKS, DJ ;
PLAYFORD, ED ;
IBANEZ, V ;
SAWLE, GV ;
THOMPSON, PD ;
FINDLEY, LJ ;
MARSDEN, CD .
NEUROLOGY, 1992, 42 (08) :1554-1560
[10]  
BULPITT CJ, 1987, LANCET, V1, P494